Neumora Therapeutics is trading at $0.73, down 5.34%, extending recent weakness despite a broader September 17, 2026 market and biotech-sector rally.
- No fresh company-specific announcement or catalyst has been identified for the session; the latest investor-relations release remains the August 14, 2026 quarterly update.
- Approximately 948,000 shares have traded versus a 1.05 million average, indicating moderate activity.